|
| 产品目录号 | GKC-LMP010045 | ||
| 产品名称 | Human CUL4B-A549 KO Cell Pool | ||
| 基因编号 | CUL4B | ||
| Uniprot_id | Q13620 | ||
| 宿主细胞 | A549 | ||
| 组织来源 | 人非小细胞肺癌细胞 | ||
| 规格 | 1×106cells/T25培养瓶或1×106cells/冻存管 | ||
| 培养基 | MEM+10%FBS+1%P/S | ||
| 筛选标记 | N/A | ||
| 生长特性 | 贴壁细胞，上皮细胞样 | ||
| 培养条件 | 37℃，5% CO2的培养箱 | ||
| 传代比例 | 1/2到1/3传代，2-3天长满 | ||
| 筛选标记 | N/A | ||
| 换液频率 | 2-3天换液 | ||
| 支原体检测结果 | 阴性 | ||
| 蛋白组验证结果 | N/A | ||
| 抗体验证结果 | N/A | ||
| 目标基因介绍 | Core component of multiple cullin-RING-based E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:14578910, PubMed:16322693, PubMed:16678110, PubMed:18593899, PubMed:29779948, PubMed:30166453, PubMed:33854232, PubMed:33854239, PubMed:22118460). The functional specificity of the E3 ubiquitin-protein ligase complex depends on the variable substrate recognition subunit (PubMed:14578910, PubMed:16678110, PubMed:18593899, PubMed:29779948, PubMed:22118460). CUL4B may act within the complex as a scaffold protein, contributing to catalysis through positioning of the substrate and the ubiquitin-conjugating enzyme (PubMed:14578910, PubMed:16678110, PubMed:18593899, PubMed:22118460). Plays a role as part of the E3 ubiquitin-protein ligase complex in polyubiquitination of CDT1, histone H2A, histone H3 and histone H4 in response to radiation-induced DNA damage (PubMed:14578910, PubMed:16678110, PubMed:18593899). Targeted to UV damaged chromatin by DDB2 and may be important for DNA repair and DNA replication (PubMed:16678110). A number of DCX complexes (containing either TRPC4AP or DCAF12 as substrate-recognition component) are part of the DesCEND (destruction via C-end degrons) pathway, which recognizes a C-degron located at the extreme C terminus of target proteins, leading to their ubiquitination and degradation (PubMed:29779948). The DCX(AMBRA1) complex is a master regulator of the transition from G1 to S cell phase by mediating ubiquitination of phosphorylated cyclin-D (CCND1, CCND2 and CCND3) (PubMed:33854232, PubMed:33854239). The DCX(AMBRA1) complex also acts as a regulator of Cul5-RING (CRL5) E3 ubiquitin-protein ligase complexes by mediating ubiquitination and degradation of Elongin-C (ELOC) component of CRL5 complexes (PubMed:30166453). Required for ubiquitination of cyclin E (CCNE1 or CCNE2), and consequently, normal G1 cell cycle progression (PubMed:16322693, PubMed:19801544). Regulates the mammalian target-of-rapamycin (mTOR) pathway involved in control of cell growth, size and metabolism (PubMed:18235224). Specific CUL4B regulation of the mTORC1-mediated pathway is dependent upon 26S proteasome function and requires interaction between CUL4B and MLST8 (PubMed:18235224). With CUL4A, contributes to ribosome biogenesis (PubMed:26711351). | ||
| 细胞系生成 | 采用CRISPR方法生成Human CUL4B-A549 KO Cell Pool | ||
| 数据说明 | Sanger 测序结果显示Human CUL4B-A549 KO Cell Pool敲除效率为100% | ||
| 应用 | 体内和体外测定 | ||
| 复苏 | 1）在37℃水浴中预热完全培养基。 2）将冻存管在 37℃水浴中解冻1-2分钟。 3）将冻存管转移到生物安全柜中，并用70%乙醇擦拭表面。 4）拧开冻存管管盖，将细胞悬液轻轻转移到含有9mL完全培养基的无菌离心管中。 5）在室温下以125g离心5-7分钟，弃上清。 6）用5mL的完整培养基重悬细胞沉淀，将细胞悬液转移到T25培养瓶中。 7）将细胞转移到37℃，5% CO2的培养箱中培养。 8）参考传代比例：1/2到1/3传代，2-5天长满。 | ||
| 传代 | 1）待培养瓶中细胞汇合度至80%-90%以上，可进行细胞传代。 2）将培养基、PBS、胰酶（0.25%Trypsin_EDTA Gibco 25200-056）等从4℃冰箱中拿出，置于37℃水浴中温度接近37℃时取出并在瓶子表面喷洒75%酒精后置于生物安全柜中。 3）从培养箱中取出待传代的培养瓶，瓶身喷洒75%酒精后置于生物安全柜中。 4）为避免冲散细胞，沿培养瓶上壁PBS润洗细胞，清洗细胞后弃去，T25加2mL。 5）加入对应体积的胰酶（T75加1.5mL，T25加0.5mL），并轻轻晃动瓶身使胰酶平铺满细胞底部。可根据实际情况适当增加或减少用量。约1-2min后大部分细胞脱落时，加入对应体积的完全培养基终止消化，并用5mL移液管轻轻吹打至细胞全部脱落。 6）将细胞悬液转移至15mL离心管，悬液300g离心5min，弃上清。 7）移取5mL完全培养基重悬细胞，按需求调整接种比例，并补充培养瓶中完全培养基，T75加至13-15mL，T25加至5mL，加1%双抗。 8）盖上瓶盖拧紧后轻轻晃动瓶身，使细胞混合均匀后置于37℃，5% CO4培养箱中。 | ||
| 细胞冻存 | 1）准备冻存液，并提前预冷。 2）确保待冻存的细胞满足冻存要求，用显微镜检查以下状态：健康的外观及形态特征、所处生长周期（对数晚期）、无污染或衰退迹象。 3）对细胞进行消化及离心处理（具体步骤参考传代培养流程） 4）按照每管1mL的量添加冻存液重悬细胞，吹打均匀后分装至冻存管。 5）将细胞放在程序降温盒中，在-80℃冰箱中冷冻。 6）后续将细胞转移到液氮罐中，以便长期储存。 | ||
| 返回 | |||
